What do systematic reviews say?

Low‐dose opioid based general anaesthesia vs high‐dose opioid based general anaesthesia

• Fast‐track cardiac care for adult cardiac surgical patients 2016 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 2486 participants
  Low

Low‐dose opioid based general anaesthesia vs high‐dose opioid based general anaesthesia

• Fast‐track cardiac care for adult cardiac surgical patients 2016 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 1394 participants
  Low

Low‐dose opioid based general anaesthesia vs high‐dose opioid based general anaesthesia

• Fast‐track cardiac care for adult cardiac surgical patients 2016 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 913 participants
  Low

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with high‐dose schedule (low certainty).

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  RR 1.2 [0.82, 1.77]
  1 study · 849 participants
  Low

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 849 participants
  GRADE not reported

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with high‐dose schedule (low certainty).

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  RR 1.33 [0.5, 3.54]
  1 study · 849 participants
  Low

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 849 participants
  GRADE not reported

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

The review found no eligible studies for this question.

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with high‐dose schedule (moderate certainty).

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  RR 1.02 [0.93, 1.11]
  1 study · 849 participants
  Moderate

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 849 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in overall survival (high certainty).

• Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
  HR 1.26 [0.7, 2.29]
  1 study · 83 participants
  High

Intervention not reported

• Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 83 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in progression‐free survival (high certainty).

• Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
  HR 1.34 [0.81, 2.2]
  1 study · 83 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  HR 0.67 [0.41, 1.07]
  2 studies · 157 participants
  Moderate

Intervention not reported

The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  HR 0.55 [0.35, 0.86]
  2 studies · 157 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  RR 0.61 [0.16, 2.22]
  2 studies · 157 participants
  Moderate

Intervention not reported

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  GRADE not reported